Monopar Q3 Loss Widens to $6.2M as Wilson Drug NDA Nears

Monopar Therapeutics Inc. (Nasdaq: MNPR) reported a third-quarter 2026 net loss of $6.2 million, or $0.72 per share, on November 12, 2026, wider than the $3.4 million, or $0.48 per share, loss booked in the same quarter of 2025. The clinical-stage biopharmaceutical company ended September 30, 2026 with $129.4 million in cash, cash equivalents and investments, and said in its quarterly release that current funds should support operations through at least March 31, 2028.

The company is simultaneously preparing a U.S. regulatory filing for its lead Wilson disease candidate, ALXN1840, and funding two radiopharmaceutical programs, so the quarter's spending reflects both a late-stage registration push and earlier-phase development.

Context — Why Monopar's Q3 2026 Results Matter Now

Monopar's loss widened even as its balance sheet grew. The company said interest income reached $1,271,370 in the third quarter of 2026, up from $655,473 a year earlier, attributing the gain to U.S. Treasury securities, commercial paper, and higher bank balances following roughly $91.9 million in net proceeds from a September 2025 capital raise.

That cash position is the backdrop for the company's regulatory timeline. Monopar announced on July 22, 2026 that it had initiated a rolling submission of a New Drug Application to the FDA for ALXN1840, and that the agency authorized the rolling format so completed sections could be reviewed while remaining sections are finalized. The company said it is on track to complete the submission within the next several weeks.

On August 19, 2026, Monopar named Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President and Head of Medical Affairs. The company said Dr. Kent is leading its medical affairs organization as it prepares for potential FDA approval of ALXN1840, and that he brings more than 20 years of biopharmaceutical leadership experience across medical affairs, clinical development and regulatory strategy.

Monopar also presented clinical data during the quarter's run-up. On November 8, 2026, the company presented baseline findings from the Phase 3 FoCus study of ALXN1840 at the American Association for the Study of Liver Diseases Liver Meeting 2026, describing it as the largest randomized controlled trial ever conducted in Wilson disease.

Wilson disease affects approximately 1 in 30,000 people worldwide, according to the company, and is caused by mutations in the ATP7B gene that impair copper excretion.

Data — What the Numbers Show

Research and development expenses for the third quarter of 2026 were $4,436,543, compared with $2,589,749 in the third quarter of 2025 — an increase of $1,846,794. Monopar attributed the rise to a $1,772,461 increase in R&D contractor and consulting expenses and a $909,699 increase in R&D personnel expenses including stock-based compensation, partly offset by a $709,250 decrease in manufacturing activities related to ALXN1840 and a net $126,116 decrease in other R&D expenses.

General and administrative expenses were $3,031,302 in the third quarter of 2026, compared with $1,503,326 a year earlier, an increase of $1,527,976. The company attributed that to a $973,753 increase in G&A personnel expenses including stock-based compensation, a $353,963 increase in G&A contractor and consulting expenses, and a net $200,260 increase in other G&A expenses.

Metric (Q3)	2026	2025
Net loss	$6.2M	$3.4M
Net loss per share	$0.72	$0.48
R&D expense	$4,436,543	$2,589,749
G&A expense	$3,031,302	$1,503,326
Interest income	$1,271,370	$655,473

The baseline FoCus data presented on November 8, 2026 showed cirrhosis rates of 39% in treatment-experienced patients and 30% in treatment-naïve patients, neurologic symptoms in 79% and 83% respectively, and psychiatric symptoms in 75% and 70%. Among evaluable patients, 73% had at least two of those manifestations. Only 47% of treatment-experienced patients fell within the guideline-recommended copper target range, and among patients on standard-of-care therapy for more than 12 months, 31% had 24-hour urinary copper excretion above that range.

Analysis — What It Means for MNPR and Biotech Peers

Monopar's quarter shows a company converting balance-sheet strength into regulatory optionality. The $129.4 million cash runway the company projects through at least March 31, 2028 covers regulatory and potential commercial activities for ALXN1840, continued development of the MNPR-101 programs, and internal research, which means the widening loss is not yet a financing concern.

The expense mix matters more than the headline loss. R&D contractor and consulting costs rose $1,772,461 while ALXN1840 manufacturing activities fell $709,250, a pattern consistent with a program moving from drug supply toward regulatory review. G&A personnel costs nearly doubled year over year, which aligns with the company's stated build-out of medical affairs ahead of a potential approval decision.

Wilson disease is a rare-disease market where first-mover claims carry weight with payers and specialist prescribers. Monopar describes ALXN1840 as a first-in-class albumin tripartite complex activator, and said the drug met its primary endpoint in the pivotal Phase 3 trial, showing copper mobilization significantly greater than standard of care over 48 weeks in both previously treated and treatment-naïve patients. The company also reported durable clinical improvement and favorable tolerability across 645 patient-years of follow-up in 266 patients.

On November 5, 2026, Monopar presented a poster at AASLD reporting neutral molybdenum balance and no molybdenum toxicity in subjects treated with ALXN1840, with serum uric acid remaining within normal limits over six years of treatment. The company said those findings are consistent with the drug's ATC mechanism and support its long-term safety profile.

The counter-argument is timing and execution. Monopar did not disclose the specific remaining NDA sections or a target action date, and a rolling submission still requires the FDA to accept and review the completed application. The baseline FoCus figures also describe disease burden in a trial population rather than a treatment effect, so they speak to unmet need, not to the probability of approval.

Positioning around the name reflects that binary. The stock trades on regulatory news flow rather than quarterly earnings, and the September 2025 raise means holders who funded the NDA push are now waiting on the FDA rather than on the income statement.

Outlook — What to Watch Next

The immediate catalyst is completion of the ALXN1840 NDA submission, which the company said is on track within the next several weeks. A second is the FDA's response to that filing, including whether the agency accepts it for review; Monopar has not disclosed a target action date.

Investors should also watch the company's cash burn against its stated runway through at least March 31, 2028. The third-quarter loss of $6.2 million, annualized against $129.4 million in cash and investments, leaves room, but R&D and G&A both stepped up sharply year over year.

Data readouts from the MNPR-101 radiopharmaceutical programs — MNPR-101-Zr in Phase 1 imaging of advanced cancers, MNPR-101-Lu in Phase 1a, and MNPR-101-Ac in late preclinical — are the other scheduled source of news flow.

Frequently Asked Questions

What does Monopar's Q3 2026 loss mean for retail investors?

The $6.2 million quarterly loss, or $0.72 per share, is larger than the $3.4 million booked a year earlier, driven mainly by higher contractor, consulting and personnel costs. Because Monopar reports no product revenue, the number that matters more is the $129.4 million in cash and investments, which the company says funds operations through at least March 31, 2028.

What happens next for the ALXN1840 FDA submission?

Monopar initiated a rolling NDA submission on July 22, 2026, and the FDA authorized the company to submit completed sections for review while it finalizes the rest. Monopar said it expects to complete the submission within the next several weeks. The company has not disclosed a target action date or the specific sections still outstanding.